Paul Choi
Stock Analyst at Goldman Sachs
(3.51)
# 853
Out of 4,868 analysts
108
Total ratings
51.43%
Success rate
4.55%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $14.87 | -79.83% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $1.29 | +520.16% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $10.90 | -54.13% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $7.47 | +7.10% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $31.90 | +63.01% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.22 | +302.68% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.57 | +40.02% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $1.10 | +172.73% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $10.30 | -2.91% | 4 | Apr 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $20 → $7 | $13.33 | -47.49% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $170.71 | +31.80% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $78.99 | +81.04% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $50.43 | -16.72% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $32.73 | +83.32% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $15.43 | +23.14% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $27.93 | +14.57% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $40.00 | +25.00% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.77 | +298.32% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $5.16 | -61.24% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.10 | +2,172.73% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $14.39 | +1,081.38% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $3.41 | +134.95% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $29.64 | +11.34% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $46.78 | +139.42% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $127.31 | +6.04% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $8.61 | +132.29% | 2 | Mar 30, 2020 |
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $14.87
Upside: -79.83%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.29
Upside: +520.16%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $10.90
Upside: -54.13%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $7.47
Upside: +7.10%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $31.90
Upside: +63.01%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.22
Upside: +302.68%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.57
Upside: +40.02%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $1.10
Upside: +172.73%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $10.30
Upside: -2.91%
Amarin Corporation
Apr 17, 2025
Maintains: Sell
Price Target: $20 → $7
Current: $13.33
Upside: -47.49%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $170.71
Upside: +31.80%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $78.99
Upside: +81.04%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $50.43
Upside: -16.72%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $32.73
Upside: +83.32%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.43
Upside: +23.14%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $27.93
Upside: +14.57%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $40.00
Upside: +25.00%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.77
Upside: +298.32%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $5.16
Upside: -61.24%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.10
Upside: +2,172.73%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $14.39
Upside: +1,081.38%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $3.41
Upside: +134.95%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $29.64
Upside: +11.34%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $46.78
Upside: +139.42%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $127.31
Upside: +6.04%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $8.61
Upside: +132.29%